Cargando…

Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA

SIMPLE SUMMARY: Synovial sarcoma is a soft-tissue sarcoma that lacks effective systemic therapy and carries poor prognosis due to frequent late local recurrence and metastases. The cancer is known to be driven in part by increased expression of the pro-survival protein BCL-2. Surprisingly, synovial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fairchild, Carter K., Floros, Konstantinos V., Jacob, Sheeba, Coon, Colin M., Puchalapalli, Madhavi, Hu, Bin, Harada, Hisashi, Dozmorov, Mikhail G., Koblinski, Jennifer E., Smith, Steven C., Domson, Gregory, Leverson, Joel D., Souers, Andrew J., Takebe, Naoko, Ebi, Hiromichi, Faber, Anthony C., Boikos, Sosipatros A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150384/ https://www.ncbi.nlm.nih.gov/pubmed/34065859 http://dx.doi.org/10.3390/cancers13102310

Ejemplares similares

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
por: Floros, Konstantinos V., et al.
Publicado: (2021)

Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models
por: Jacob, Sheeba, et al.
Publicado: (2022)

Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1
por: Kurupi, Richard, et al.
Publicado: (2022)

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy
por: Floros, Konstantinos V., et al.
Publicado: (2018)

High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition
por: Cai, Jinyang, et al.
Publicado: (2022)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

Structural Mechanism for Regulation of Bcl-2 protein Noxa by phosphorylation
por: Karim, Christine B., et al.
Publicado: (2015)

Erratum: Structural Mechanism for Regulation of Bcl-2 protein Noxa by phosphorylation
por: Karim, Christine B., et al.
Publicado: (2015)

Immunotherapy for Prostate Cancer Enters Its Golden Age
por: Boikos, Sosipatros A., et al.
Publicado: (2012)

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X(L)–BAX interaction
por: Saleh, Tareq, et al.
Publicado: (2020)

SAT-300 Evading Death: Noxa in Cushing’s Disease Pituitary Adenomas
por: Alvarez, Reinier, et al.
Publicado: (2020)

NOXA-dependent contextual synthetic lethality of BCL-XL inhibition and “osmotic reprogramming” in colorectal cancer
por: Knoll, Gertrud, et al.
Publicado: (2020)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

Apoptosis induced by overall metabolic stress converges on the Bcl-2 family proteins Noxa and Mcl-1
por: Wensveen, Felix M., et al.
Publicado: (2011)

The Laminin-α1 Chain-Derived Peptide, AG73, Binds to Syndecans on MDA-231 Breast Cancer Cells and Alters Filopodium Formation
por: Puchalapalli, Madhavi, et al.
Publicado: (2019)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer
por: Zhang, Haichao, et al.
Publicado: (2015)

NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
por: Liu, Yuxuan, et al.
Publicado: (2018)

NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice
por: Puchalapalli, Madhavi, et al.
Publicado: (2016)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Advances and Challenges on Management of Gastrointestinal Stromal Tumors
por: Mei, Lin, et al.
Publicado: (2018)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines
por: Lam, Lloyd T, et al.
Publicado: (2015)

Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment
por: Neely, Victoria, et al.
Publicado: (2023)

Roscovitine-induced Apoptosis in Neutrophils and Neutrophil Progenitors Is Regulated by the Bcl-2-Family Members Bim, Puma, Noxa and Mcl-1
por: Gautam, Sanjivan, et al.
Publicado: (2013)

Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
por: Golla, Carolin, et al.
Publicado: (2021)

Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma
por: Dengler, M A, et al.
Publicado: (2014)

Correction: Roscovitine-induced Apoptosis in Neutrophils and Neutrophil Progenitors Is Regulated by the Bcl-2-Family Members Bim, Puma, Noxa and Mcl-1
por: Gautam, Sanjivan, et al.
Publicado: (2014)

NOXA as critical mediator for drug combinations in polychemotherapy
por: Ehrhardt, H, et al.
Publicado: (2012)

A179L, a viral Bcl-2 homologue, targets the core Bcl-2 apoptotic machinery and its upstream BH3 activators with selective binding restrictions for Bid and Noxa
por: Galindo, Inmaculada, et al.
Publicado: (2008)

SATB1 Mediates Long-Range Chromatin Interactions: A Dual Regulator of Anti-Apoptotic BCL2 and Pro-Apoptotic NOXA Genes
por: Yang, Yin, et al.
Publicado: (2015)

The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA
por: Muenchow, Alina, et al.
Publicado: (2020)

Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells
por: Vera, Mariana Belén, et al.
Publicado: (2022)

Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors
por: Leverson, Joel D.
Publicado: (2015)

Aspirin Induced Glioma Apoptosis through Noxa Upregulation
por: Chang, Cheng-Yi, et al.
Publicado: (2020)

NOXA Is Important for Verticillium dahliae’s Penetration Ability and Virulence
por: Zhu, Xiaohan, et al.
Publicado: (2021)

Intimal sarcoma of the pulmonary artery treated with neoadjuvant radiation prior to pulmonary artery resection and reconstruction
por: Allen, Alexander, et al.
Publicado: (2021)

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
por: Leverson, Joel D., et al.
Publicado: (2018)

Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers
por: Ebi, Hiromichi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pfg4ik8essb797s10r7eci0lkc